Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Solbinsiran · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Solbinsiran | EXPERIMENTAL | Participants will receive solbinsiran subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Name | Type | Description |
|---|---|---|
| Solbinsiran | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history * Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart) * Have a body mass index (BMI) within the range of 18.5 to 45.0 kil...
Solbinsiran is an investigational small molecule being developed for severe hypertriglyceridemia, a condition marked by very high levels of triglycerides in the blood. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Solbinsiran is a small interfering RNA (siRNA) that targets a specific gene to reduce the production of proteins involved in triglyceride metabolism. By silencing this target, it aims to lower triglyceride levels in patients with severe hypertriglyceridemia.
Solbinsiran is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 2 clinical trials for severe hypertriglyceridemia.
Solbinsiran is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. A Phase 2 trial is currently recruiting participants to evaluate its safety and efficacy.
Solbinsiran is being studied in a Phase 2 clinical trial with the identifier NCT07269210. This randomized, double-blind, placebo-controlled study enrolls approximately 60 participants with severe hypertriglyceridemia across the United States, Canada, China, and Japan.
Yes, Solbinsiran is also known as LY3561774. The clinical trial NCT07269210, which is studying Solbinsiran in severe hypertriglyceridemia, uses this alternative name in its official title.